Spruce Biosciences, Inc. (SPRB)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
40.35 USD
-2.52
(-5.878%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:47 a.m. EDT
The immediate outlook is severely clouded by a relentless downward trend and deteriorating financial health. Over the last five years, the stock has lost nearly 99.8% of its value, with the most recent annual performance showing a catastrophic -92.94% decline. This is compounded by four out of five years of negative growth, signaling a business model that is failing to generate traction or revenue. Fundamentally, the company is bleeding cash, with free cash flow and operating cash flow both deeply negative, while returning negative equity to shareholders. Although analysts project a turnaround and offer a high target price, these figures are disconnected from the reality of a company with no earnings, massive losses, and a balance sheet that cannot sustain operations without further capital raises. There is no dividend to provide income, and the recent price action shows continued weakness, trading well below moving averages. The combination of structural decline, cash burn, and lack of profitability makes this a dangerous hold for any timeframe. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.145803 |
| AutoARIMA | 0.152359 |
| AutoETS | 0.152360 |
| AutoTheta | 0.173581 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 9.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.406 |
| Excess Kurtosis | -0.90 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.163 |
| Market Cap | 115,966,424 |
| Forward P/E | 8.11 |
| Beta | 3.30 |
| Website | https://sprucebio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7576734 |
| Address1 | 611 Gateway Boulevard |
| Address2 | Suite 740 |
| All Time High | 200,250.0 |
| All Time Low | 7.0 |
| Ask | 51.86 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 73,850 |
| Average Daily Volume3 Month | 77,632 |
| Average Volume | 77,632 |
| Average Volume10Days | 73,850 |
| Beta | 3.302 |
| Bid | 30.6 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 30.416 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 40.35 |
| Current Ratio | 9.227 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 42.91 |
| Day Low | 40.19 |
| Debt To Equity | 9.163 |
| Display Name | Spruce Biosciences |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,259,200 |
| Earnings Timestamp Start | 1,754,909,940 |
| Ebitda | -39,037,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.7 |
| Enterprise Value | 27,343,424 |
| Eps Current Year | -25.3175 |
| Eps Forward | 4.975 |
| Eps Trailing Twelve Months | -39.12 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 51.5377 |
| Fifty Day Average Change | -11.187702 |
| Fifty Day Average Change Percent | -0.21707803 |
| Fifty Two Week Change Percent | -75.76734 |
| Fifty Two Week High | 188.25 |
| Fifty Two Week High Change | -147.9 |
| Fifty Two Week High Change Percent | -0.78565735 |
| Fifty Two Week Low | 40.19 |
| Fifty Two Week Low Change | 0.15999985 |
| Fifty Two Week Low Change Percent | 0.003981086 |
| Fifty Two Week Range | 40.19 - 188.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,602,250,200,000 |
| Float Shares | 2,016,925 |
| Forward Eps | 4.975 |
| Forward P E | 8.110553 |
| Free Cashflow | -20,647,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 22 |
| Fullday Change | -2.5200005 |
| Fullday Change Percent | -5.8782377 |
| Fullday Price | 40.35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -22,953,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03374 |
| Held Percent Institutions | 0.76875997 |
| Implied Shares Outstanding | 2,874,013 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,025-09-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,754,524,800 |
| Last Split Factor | 1:75 |
| Long Business Summary | Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California. |
| Long Name | Spruce Biosciences, Inc. |
| Market | us_market |
| Market Cap | 115,966,424 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_417731313 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -51,353,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 141,990,612 |
| Number Of Analyst Opinions | 9 |
| Open | 42.8 |
| Operating Cashflow | -42,624,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Phone | 415 343 5986 |
| Previous Close | 42.87 |
| Price Eps Current Year | -1.5937593 |
| Price Hint | 2 |
| Price To Book | 1.3266044 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.784 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | -2.52 |
| Regular Market Change Percent | -5.87824 |
| Regular Market Day High | 42.91 |
| Regular Market Day Low | 40.19 |
| Regular Market Day Range | 40.19 - 42.91 |
| Regular Market Open | 42.8 |
| Regular Market Previous Close | 42.87 |
| Regular Market Price | 40.35 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 110,571 |
| Return On Assets | -0.40033 |
| Return On Equity | -1.05981 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 2,874,013 |
| Shares Percent Shares Out | 0.15020001 |
| Shares Short | 431,541 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 440,243 |
| Short Name | Spruce Biosciences, Inc. |
| Short Percent Of Float | 0.1517 |
| Short Ratio | 4.02 |
| Source Interval | 15 |
| State | CA |
| Symbol | SPRB |
| Target High Price | 230.0 |
| Target Low Price | 104.0 |
| Target Mean Price | 148.0 |
| Target Median Price | 144.0 |
| Total Cash | 96,295,000 |
| Total Cash Per Share | 33.505 |
| Total Debt | 7,672,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -39.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 58.472527 |
| Two Hundred Day Average Change | -18.122528 |
| Two Hundred Day Average Change Percent | -0.30993235 |
| Type Disp | Equity |
| Volume | 110,571 |
| Website | https://sprucebio.com |
| Zip | 94,080 |